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Introduction 
A vaccine for reducing the risk for developing herpes zoster (HZ) was approved by the US Food 
and Drug Administration (FDA) and licensed for use in 2006.  In 2008, the Advisory Committee on 
Immunization Practices (ACIP) recommended administering the vaccine to adults aged 60 years and older 
(Hales, Harpaz, Ortega-Sanchez, & Bialek, 2014; Tseng et al., 2011).  Care providers were hopeful that 
use of the vaccine would occur and thus, decrease the incidence of HZ and post-herpetic neuralgia that, 
in turn, would reduce the cost of managing HZ.  This has not been the case. According to the Centers for 
Disease Control and Prevention (CDC), the vaccination coverage level for the age group of 60 and over is 
15.8%, as compared to 54.4% for pneumonia and 68% for influenza in the same age group (Centers for 
Disease Control and Prevention [CDC], 2014). 
Problem Identification 
The project’s principal investigator, a Nurse Practitioner at a facility for assisted-living and long-
term care, noticed that the existing vaccination protocols at the facility did not include HZ vaccination.  
The on-site pharmacy did not store the vaccine as there was no call for it. Despite the incidence of 
reported cases of HZ in the facility, patients were not offered the HZ vaccine. Screening for specific 
vaccines was limited to state-mandated vaccines, such as for pneumonia and influenza.  While providers 
generally agreed on the need to follow national guidelines in managing chronic conditions, there seemed 
to be a disconnect in applying national recommendations for the prevention of HZ.  In general, both 
providers and residents seemed to not be aware of the availability and benefits of the vaccine. 
Background and Significance of HZ and the HZ Vaccine 
Approximately 1 million episodes of HZ occur annually, and half of all cases occur in men and 
women 60 years old or older (CDC, 2014).  One-third of persons who have had a varicella zoster virus 
infection (Chicken Pox) will develop HZ during their lifetime (Chua & Chen, 2010).  The incidence of 
Herpes Zoster in long-term care facilities is a problem because the pain of HZ and of post-herpetic 
neuralgia is debilitating and often long lasting.  Herpes zoster, caused by reactivation of the varicella 
zoster virus dormant in the dorsal root ganglia of people who had contracted the virus, increases with 
age, mainly as a result of declining immunity (Harpaz, Ortega-Sanchez, & Seward, 2008; Watkins, 2010).  
Efficacy of the vaccine was demonstrated in the pre-licensing trials. Oxman et al. (2005) reported 
that in two large-scale randomized controlled trials (the Zoster Efficacy and Safety Trial and the Shingles 
Prevention Study), a live vaccine that increases varicella-specific immunity in immunocompetent persons 
proved to be partially effective (51% in the Shingles Prevention Study) in preventing HZ in older adults.  
Tseng et al. (2011) in a retrospective cohort study, matched persons with and without vaccination in a 
sample of older community dwelling adult persons and found similar results.  The authors reported 6.4 
incidences per 1000 for vaccinated persons 60 and older vs. 13 per 1000 for unvaccinated persons. 
Although state mandates may require that long-term care residents be screened for and offered 
vaccination for pneumonia and influenza, vaccination for herpes zoster is not usually on state-mandated 
rosters.  However, despite the cost-effectiveness of clinical preventive services, the percentage of older 
adults who are up to date with core services is low (Department of Health and Human Services, 2010).  
Less than half of adults 65 years and older, and 25% of adults 50-64 years old, report being up to date 
with coverage (Shenson, Adams, Bolen & Anderson, 2011).  
Purpose of the HZ Vaccine Initiative  
The HZ vaccination initiative was conducted to determine whether a systematic approach would 
increase the number of residents vaccinated against HZ in a long-term care and assisted living facility.  
The goal was to ultimately decrease the incidence of HZ.  To achieve a systematic approach, an overall 
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design for developing, implementing, and evaluating the initiative was developed.  In the pre-project 
development phase, presentations were made to key stakeholders, staff, and residents to introduce the 
initiative and gain support.  Once approval was obtained, awareness and educational sessions were 
developed. Before project implementation, a protocol for HZ screening and administration was devised.  
Baseline information was collected from resident medical records to determine both the number of 
residents who had been vaccinated and the number of incidences occurring in the previous 12 months.  
The HZ vaccine initiative sought to increase awareness among providers, staff, and residents 
about the availability, accessibility, safety, and efficacy of the HZ vaccine; to identify barriers to 
protocol implementation; and to identify partners necessary to accomplish project aims.  In addition, 
the initiative aimed to develop an algorithm that would aid providers and staff in screening persons for 
vaccinations and standardize a protocol for administering the vaccination.  The intent was to screen all 
incoming or new admittances to the facility for HZ during the 6-month implementation period.  
Therefore, the initiative was limited to screening and vaccination of incoming residents only.  
Methods 
Context 
The setting for the HZ vaccine project was a 200-resident nursing home and assisted living facility 
in a large southwestern city.  The facility’s Medical Director, Administrator, Director of Nursing, and 
Assistant Director of Nursing were involved in planning, developing, and then implementing the HZ 
initiative.  The facility’s clinical staff included two physicians and seven nurse practitioners who served 
to meet the residents’ medical needs.  The clinicians provided clinical care to minimize unnecessary 
patient isolation, hospitalizations, and emergency room visits.  
Vaccine Availability and Reimbursement 
Because the on-site pharmacy does not stock HZ vaccine, a partnering arrangement was made 
with a neighboring facility for delivery of the vaccine at call.  Payment options included out-of-pocket, 
private insurance, or Medicaid or Medicare. Insurance usually covered the cost of the HZ vaccine for 
residents in the acute and rehabilitation phase of the facility, whereas the vaccine cost for residents in 
the long-term facility were through Medicaid or Medicare part D for qualifying patients.  When a resident 
or patient agreed to receive the vaccine, the pharmacy was updated to as to his or her insurance carrier. 
Intervention 
The intervention was a 6-month period following a 3-month planning phase.  During the 3-month 
pre-implementation phase, the initiative staff developed project components, which included education 
materials, a screening algorithm and vaccination protocol, vaccination forms, and a standing order for 
clinicians to order the HZ vaccine at need.  The intervention was limited to intake of new admittances 
to the facility.  Persons joining both the nursing home and assisted living components of the facility 
during the 6 month implementation period were screened for HZ.  This resulted in a corresponding low 
number of vaccinations in the 6 month period (n = 4) as few residents were admitted during the time 
frame and not all admittances qualified for vaccination.  
Education 
A 30-minute educational training program was presented on a monthly basis for 3 months prior 
to screening persons newly admitted to the facility for HV.  Sessions were open to nurses, medication 
aides, nursing assistants, clinical providers, and residents.  PowerPoint presentations provided basic 
knowledge about the incidence of HZ, costs to the facility in managing HZ, payment options, and vaccine 
availability, cost, side effects, benefits, and administration schedule.  Merck & Co, licensee of 
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ZOSTAVAX® (live HZ vaccine), provided an online module that focused on clinical aspects of the vaccine, 
such as prescribing, dosing, and ensuring patient safety.   
Clinical providers (7 NPs and 2 physicians) completed a survey prior to and at the end of the 6-
month implementation period.  The survey was based on a similar form for influenza (Nexøe, Kragstrup, 
& Søgaard, 2009).  The providers (n = 9) and other nursing staff (n= 12) also completed a test before and 
after the training to obtain a pre- to post-test difference in scores. 
Screening Algorithm 
 On patient admission to the facility, the admission director screens the resident and/or 
caregiver to determine whether the patient was vaccinated for HZ, tuberculosis, pneumonia, and 
influenza.  The Yes-No paths were as follows: 
Question: Has resident been vaccinated for HZ?  
Path 1 if Yes for HZ.  Screen for state-mandated vaccines.  
If Yes, notate record. 
If No, refer to vaccination protocol and inform pharmacy.  
Path 2 if No for HZ. Screen for state-mandated vaccines 
If Yes for state-mandated, notate record.  
If No, go to HZ protocol and follow up with state-mandated vaccination protocol. 
HZ Vaccination Protocol 
A protocol for guiding clinicians through the process of patient evaluation and HZ vaccine 
administration was developed in consultation with the facility administration, pharmacy, and nursing 
staff (See Appendix A).  Steps of the HZ protocol accomplished in the implementation phase of the 
initiative are as follows: 
1. The admitting nurse determines the patient’s eligibility for HZ vaccination payment. 
2. The clinical provider (nurse practitioner or physician) assesses the patient to ascertain if 
patient is immunocompetent and for contraindications to taking the HZ vaccine. The 
provider makes the final decision to vaccinate or not.  
3.  If the clinical provider recommends HZ vaccination, the standing order for the vaccine 
goes into effect.  
a. The partnering pharmacy is notified. 
b. The pharmacy delivers the HZ vaccine to the facility. 
4. The nurse obtains permission and a vaccination consent form the patient or legally 
responsible party.  
5. The nurse vaccinates the patient. 
 
Evaluation 
Prior to attending the educational components, clinical providers (n = 9) completed a survey to 
determine their comfort level with recommending the HZ vaccine.  One item of the 6-item questionnaire 
asked respondents to rate their knowledge about the use of the vaccine and another asked what 
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limitation kept them from routinely ordering the vaccination.  The clinicians’ initial responses constituted 
baseline information.  The survey was repeated 6 months later. The initiation team completed a baseline 
review of vaccination records in patient charts to determine the number of residents who had been 
vaccinated for HZ (n = 52 charts for long-term care residents and n = 70 charts for residents in assisted 
living). Noted also were the number of residents treated for HZ in the prior 12 months.  This chart review 
was repeated at 3 months and 6 months after the rollout of the HZ vaccine protocol. 
Initiative Approval and Ethical Considerations 
The project’s research protocol was submitted to the Institutional Review Board of the project 
manager’s university for review and was granted approval as a quality improvement initiative.  Approval 
was also obtained from the facility’s administrators, who ensured that no conflicts of interest existed.  
Protection of the patients’ identities was maintained and assured. Because the vaccine used is FDA 
approved, the measures applied were within the expected standard of care. Each resident or his or her 
responsible party or guardian gave consent for vaccination when requested for administration.  The 
vaccine manufacturer’s support for the project was limited to educational posters and on-line materials 
for the clinicians.  The facility or project coordinator received no monetary gains from Merck & Co. or 
the partnering pharmacy.   
Results 
Nine clinicians (7 nurse practitioners and 2 physicians) participated in the HZ initiative. Survey 
results are reported in Appendix A.  Prior to the educational component of the program, 2 of the 9 
providers reported they had recommended the vaccine. After the 6-month implementation period, the 
number increased to 8. That incidences were occurring was evident.  Participants reported that they had 
managed treatment of 8 patients with shingles before the initiative and an additional 2 (total of 10) 
during the 6-month period.  Whereas the providers’ comfort level increased markedly, from 2 “most 
comfortable” to 8, they felt restricted in their effectiveness in providing HZ vaccination.  Eight of the 
clinicians reported that lack of facility support was the chief limiting factor. Reasons at baseline 
identified for not recommending the vaccine were the high cost of vaccine and insurance coverage issues 
(44%) and lack of awareness of the vaccine (22%).  However, all participants at 6 months rated themselves 
as “most knowledgeable” of the vaccine, and cost and lack of awareness were not given as barriers to 
prescribing the vaccination.  
During the 6 month period, all persons admitted to the facility were screened for HZ vaccination.  
The providers followed the steps of the HZ protocol and offered the vaccine accordingly.  Four persons, 
all new residents in assisted living, met the vaccination criterion and agreed to the vaccination.  The 
increase from baseline is shown in Figure 1.  
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Figure 1: Number of Residents Vaccinated with HZ Vaccine at 3 and 6 Months 
 
 
The percentage of increase in pre- and posttest analysis (n = 21) showed a significant increase. 
Whereas 51% of test respondents answered correctly on the pretest, 83% answered correctly on the 
posttest.  This showed a 32% pre- to posttest difference in knowledge of HV and the vaccine.  
Discussion 
Changes in Processes of Care at Facility 
Prior to the HZ initiative, the HZ vaccination status of the residents was not included on the 
standard patient intake and screening form.  A review of resident charts (total n=122) showed that no 
vaccinations had been given in the previous 12 months, although incidences of shingles had occurred.  To 
support the initiative, the NH facility implemented standing orders for the HZ vaccine for 
immunocompetent residents who met the vaccine administration criteria.  The HZ vaccine standing 
orders empowered the nursing staff (including registered nurses and licensed vocational nurses) to make 
the decision to vaccinate based on the developed HZ vaccine criteria and HZ protocol guidelines. To 
facilitate the process, patient intake and screening forms were redesigned to include HZ vaccine on the 
list of vaccines offered by the facility.  
The facility did not store the HZ vaccine on premises.  The HZ vaccine had not previously been 
offered, and the on-site pharmacy did not have the conditions for maintaining potency at the required 
low temperatures.  This issue was addressed through partnering with a pharmacy close to the nursing 
home facility that could provide expedient access to the vaccine when required.   
Screening Implementation 
After the implementation of the HZ Vaccine initiative, screening for HZ vaccine coverage for 
newly admitted residents increased from no screening of residents for prior HZ vaccine coverage to 100% 
screening.  All residents admitted to the facility were screened for prior HZ vaccination and offered the 
HZ vaccine.  Because the baseline for comparative purposes derived from chart reviews was 0%, any 
vaccination that occurred represented an improvement.  The intent was that as HZ screening commenced 
and facility administrators and clinical staff became more aware of the need for decreasing the incidence 
of shingles in the facility’s residents, the percentage of vaccination would increase.  Of note is that not 
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all residents would or did meet eligibility criteria due to suppressed immune systems and ongoing 
treatments (e.g. chemotherapy, HIV antiviral therapy).   
The role of education in increasing staff awareness of HZ and the vaccine was profound.  The 
proof was seen in the providers’ willingness to recommend vaccination after 6 months and a 32% increase 
in providers’ knowledge of HZ and the vaccine from baseline.  Because admittance protocols were not 
following national guidelines for the prevention of HZ, the implementation of a screening and vaccination 
protocol was of value to the facility.  Ongoing education brought an awareness of national guidelines 
that refocused the providers’ attention and consequently improved the health outcomes of the facility’s 
residents.   
A success measure of the HZ vaccine initiative was that the clinical practice group, members of 
which also practiced in other long-term care facilities, wanted to implement the HZ vaccine initiative at 
those other facilities.  This raises the expectation that replicating this initiative in similar facilities can 
reduce HZ occurrence and lower costs associated with managing the disease.  Future efforts should be 
geared toward changing Medicare policy on vaccination to mandate that the HZ vaccine be offered in 
long-term care facilities.  
Conclusion 
Herpes Zoster remains a common infection in the U.S. despite the availability of an effective and 
safe vaccine.  The HZ vaccination initiative in one targeted institution increased awareness among 
providers, staff, and patients about HZ vaccine availability, accessibility, safety, efficacy, and cost.  Not 
offering the vaccine can potentially cause a financial burden for the healthcare system and decreased 
quality of health and well-being for patients. Concerted efforts on the part of clinical providers, facility 
administrators, pharmacists, and nurse practitioners to update protocols and recommend vaccination at 
time of resident admittance to the facility can result in decreased incidence of herpes zoster and 
improved quality of care for long-term care residents.  
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Appendix A: Provider Comfort Level with Herpes Zoster Vaccine 
PROVIDER QUESTIONS BASELINE 6 MONTHS POST- 
IMPLEMENTATION 
Have you ordered Zostavax for 
any of your residents/patients 
in the last year?  Y/N 
Yes = 2 
No = 7 
Yes = 6 
No =  2 
No response = 1 
Have managed any patient with 
herpes zoster (shingles) in the 
last 3 months Y/N 
Yes = 5 
No =  4 
Yes = 5 
No  = 4 
 
If Yes, how many? Total patients treated 
for HZ  = 8  
Total patients treated 
for HZ  =10  
How comfortable are you 
recommending Zostavax to your 
patients?  On a scale of 1-5 
where 1 is least Comfortable and 
5 is most comfortable 
Least comfortable 
1 = 2 
2 = 3 
3 = 1  
4 = 1 
5 = 2  
Most comfortable 
Least comfortable 
1 = 0 
2 = 0 
3 = 0 
4 = 1 
5 = 8  
Most comfortable 
How would you rate yourself in 
regards to your knowledge 
about the safety and use of 
Zostavax (i.e. dosage, side 
effects, adverse effects and 
contraindications) on a scale of 
1-5: 1 = least knowledgeable,  
       5 = very knowledgeable 
Least knowledgeable 
1 = 0  
2 = 2 
3 = 2 
4 = 3 
5 = 2 
Most knowledgeable   
Least knowledgeable 
1 = 0  
2 = 0  
3 = 0 
4 = 0 
5 = 9 
Most knowledgeable            
What limitation if any bars you 
from ordering Zostavax 
routinely as you do Pneumovax 
or flu vaccines? Describe briefly 
No limitations    n = 1 
Costs                 n = 4 
Lack of              n = 2 
information          
Lack of facility   n = 1 
support    
No response        n = 1            
No limitations    n = 1 
Costs                 n = 0 
Lack of              n = 0 
information        
Lack of facility   n = 8 
support   
No response        n = 0               
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Appendix B: HZ Vaccination Protocol 
 
 
                                       Yes 
                                                                                                       
 
 
 
 
 
 
Has resident been vaccinated 
for Herpes zoster ?
Patient has no  
contraindications to Zostavax 
including immunosuppresion,  
HIV, Recent Chemotherapy, 
Steroid therapy or Allergy to 
vaccines?
Nurse offers  vaccine to 
resident & resident or 
responsible party signs 
consent form
if yes, Screen for other 
Mandated Vaccines 
(Pneumovax, & Influenza)
Vaccinate, monitor 
and report any 
adverse effects to 
clinical provider
Notify partnering 
Pharmacy to avail 
vaccine
Verify Insurance 
coverage for 
Zostavax
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